Key Financial Results (Standalone)

Quarter Ended September 30, 2026 (Q2 FY27):

  • Revenue from operations: ₹613.15 lakhs
  • Other operating income: ₹101.59 lakhs
  • Other Income: ₹42.41 lakhs
  • Total Income: ₹757.15 lakhs
  • Total Expenses: ₹1,099.24 lakhs (Employee benefits: ₹469.30 lakhs, Depreciation: ₹181.53 lakhs, Other expenses: ₹448.41 lakhs)
  • Loss before tax: ₹(342.09) lakhs
  • Tax income: ₹84.76 lakhs (Deferred tax)
  • Net Loss for the quarter: ₹(257.33) lakhs
  • Total Comprehensive Loss for the quarter: ₹(256.17) lakhs
  • Basic & Diluted Loss per share (₹10 face value): (₹0.42)

Half Year Ended September 30, 2026 (H1 FY27):

  • Revenue from operations: ₹1,572.79 lakhs
  • Other operating income: ₹203.17 lakhs
  • Other Income: ₹85.98 lakhs
  • Total Income: ₹1,861.94 lakhs
  • Total Expenses: ₹2,264.10 lakhs
  • Loss before tax: ₹(402.16) lakhs
  • Tax income: ₹99.28 lakhs (Deferred tax)
  • Net Loss for the half year: ₹(302.88) lakhs
  • Total Comprehensive Loss for the half year: ₹(300.55) lakhs
  • Basic & Diluted Loss per share (₹10 face value): (₹0.50)

Balance Sheet Highlights (Standalone) as at September 30, 2026

  • Total Assets: ₹10,987.56 lakhs (Mar 31, 2026: ₹11,115.35 lakhs)
  • Non-current assets: ₹7,387.94 lakhs (Property, plant and equipment: ₹6,549.06 lakhs)
  • Current assets: ₹3,599.62 lakhs (Cash and cash equivalents: ₹2,854.12 lakhs; Trade receivables: ₹187.07 lakhs)
  • Total Equity: ₹9,212.35 lakhs (Equity share capital: ₹6,103.06 lakhs; Other equity: ₹3,109.29 lakhs)
  • Total Liabilities: ₹1,775.21 lakhs

Cash Flow Statement (Standalone) for H1 FY27

  • Net cash used in operating activities: ₹(338.36) lakhs
  • Net cash used in investing activities: ₹(513.17) lakhs (Payment for purchase of property, plant & equipment: ₹593.29 lakhs)
  • Net cash from financing activities: ₹0.00 lakhs
  • Net decrease in cash and cash equivalents: ₹(174.81) lakhs

Other Material Disclosures

  • The financial results have been reviewed by the statutory auditors, M/s. GSKA & Co., Chartered Accountants, who issued an unmodified review report.
  • The results are prepared in accordance with Ind AS.
  • Other operating income of ₹203.17 lakhs (H1 FY27) relates to rentals for the Biotech facility and equipment leased to Sun Pharmaceutical Industries Limited for R&D activities.
  • The Company has only one reportable segment: Pharmaceuticals.
  • The company notes that its overseas subsidiaries (Zenotech Farmaceutica Do Brasil Ltda and Zenotech Inc) are defunct/cancelled. Zenotech Laboratories Nigeria Limited has a winding up order, but related RBI filings are pending. The company believes it has no subsidiaries as per Ind AS 110.
  • The company believes that legacy matters pertaining to periods prior to November 12, 2011, have been abated/settled and any remaining financial impact is not material.